Patents Assigned to Cancer Targeted Technology LLC
  • 18F-labeled PSMA-targeted PET imaging agents
    Patent number: 11554183
    Abstract: Compounds of Marlush formula (I) described in the claims are useful in diagnostic methods for detecting and/or identifying cells presenting PSMA. Disclosed are also methods for preparing the compounds.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 17, 2023
    Assignees: CANCER TARGETED TECHNOLOGY LLC, WASHINGTON STATE UNIVERSITY
    Inventors: Clifford Berkman, Svetlana A. Stekhova
  • Chelated PSMA inhibitors
    Patent number: 11225496
    Abstract: Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. Also provided are compositions including a compound of Formula (I) together with a pharmaceutically acceptable carrier, and methods for imaging prostate cancer cells.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: January 18, 2022
    Assignee: Cancer Targeted Technology LLC
    Inventors: Clifford Berkman, Cindy Choy
  • Albumin-binding PSMA inhibitors
    Patent number: 11147889
    Abstract: Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L1 and L2 are each independently a covalent bond or a divalent linking group, R is a detectable label or therapeutic drug and B is an albumin binding moiety. Also provided are compositions including a compound of Formula (I) together with a pharmaceutically acceptable carrier, and methods for imaging prostate cancer cells using a compound of Formula (I).
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: October 19, 2021
    Assignee: Cancer Targeted Technology LLC
    Inventors: Clifford Berkman, Cindy Choy
  • Chelated PSMA inhibitors
    Patent number: 10166301
    Abstract: Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: January 1, 2019
    Assignee: CANCER TARGETED TECHNOLOGY LLC
    Inventors: Clifford Berkman, Bea Langton-Webster, Xiaobing Wang
  • Chelated PSMA inhibitors
    Patent number: 9974869
    Abstract: Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: May 22, 2018
    Assignee: Cancer Targeted Technology LLC
    Inventors: Clifford Berkman, Bea Langton-Webster, Xiaobing Wang
  • Chelated PSMA inhibitors
    Patent number: 9446157
    Abstract: Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: September 20, 2016
    Assignee: Cancer Targeted Technology LLC
    Inventors: Clifford Berkman, Bea Langton-Webster, Xiaobing Wang
  • Chelated PSMA Inhibitors
    Publication number: 20140241985
    Abstract: Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.
    Type: Application
    Filed: June 13, 2012
    Publication date: August 28, 2014
    Applicant: CANCER TARGETED TECHNOLOGY LLC
    Inventors: Clifford Berkman, Bea Langton-Webster, Xiaobing Wang
  • Peptidomimetic inhibitors of PSMA, compounds comprising them, and methods of use
    Patent number: 8293725
    Abstract: Compounds of the formula, A-L-B, wherein A is glutamate or a glutamate analog; L is a phosphoramidate or a phosphoramidate analog; and B is serine or a serine analog are described which are potent inhibitors of prostate-specific membrane antigen (PMSA). Such compounds are useful in treatment of prostate cancer; and when chemically attached to a fluorescent dye, can efficiently and selectively label prostate cancer cells for fluorescent imaging.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: October 23, 2012
    Assignee: Cancer Targeted Technology LLC
    Inventor: Cliff Berkman
  • Peptidomimetic Inhibitors Of PSMA, Compounds Comprising Them, And Methods Of Use
    Publication number: 20100183517
    Abstract: Compounds of the formula, A-L-B, wherein A is glutamate or a glutamate analog; L is a phosphoramidate or a phosphoramidate analog; and B is serine or a serine analog are described which are potent inhibitors of prostate-specific membrane antigen (PMSA). Such compounds are useful in treatment of prostate cancer; and when chemically attached to a fluorescent dye, can efficiently and selectively label prostate cancer cells for fluorescent imaging.
    Type: Application
    Filed: January 22, 2010
    Publication date: July 22, 2010
    Applicant: CANCER TARGETED TECHNOLOGY LLC
    Inventor: Cliff Berkman
  • Peptidomimetic Inhibitors Of PSMA, Compounds Comprising Them, And Methods of Use
    Publication number: 20070219165
    Abstract: Compounds of the formula, A-L-B, wherein A is glutamate or a glutamate analog; L is a phosphoramidate or a phosphoramidate analog; and B is serine or a serine analog are described which are potent inhibitors of prostate-specific membrane antigen (PMSA). Such compounds are useful in treatment of prostate cancer; and when chemically attached to a fluorescent dye, can efficiently and selectively label prostate cancer cells for fluorescent imaging.
    Type: Application
    Filed: March 14, 2007
    Publication date: September 20, 2007
    Applicant: CANCER TARGETED TECHNOLOGY LLC
    Inventor: Cliff Berkman
  • Peptidomimetic inhibitors of PSMA, compounds comprising them, and methods of use
    Patent number: RE42275
    Abstract: Compounds of the formula, A—L—B, wherein A is glutamate or a glutamate analog; L is a phosphoramidate or a phosphoramidate analog; and B is serine or a serine analog are described which are potent inhibitors of prostate-specific membrane antigen (PMSA). Such compounds are useful in treatment of prostate cancer; and when chemically attached to a fluorescent dye, can efficiently and selectively label prostate cancer cells for fluorescent imaging.
    Type: Grant
    Filed: July 13, 2010
    Date of Patent: April 5, 2011
    Assignee: Cancer Targeted Technology LLC
    Inventor: Clifford E. Berkman